ANI Other Current Liab vs Current Deferred Revenue Analysis

ANIP Stock

USD 58.92 0.27 0.46%

ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Other Current Liab and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.

Other Current Liab vs Current Deferred Revenue

Other Current Liab vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Other Current Liab account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between ANI Pharmaceuticals' Other Current Liab and Current Deferred Revenue is 0.62. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Other Current Liab and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of ANI Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Other Current Liab i.e., ANI Pharmaceuticals' Other Current Liab and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.62

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Other Current Liab

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.At this time, ANI Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 02/16/2025, Enterprise Value Over EBITDA is likely to grow to 11.97, while Issuance Of Capital Stock is likely to drop slightly above 71.8 M.

ANI Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Stockholder Equity	Short Long Term Debt Total	Short Term Debt	Current Deferred Revenue	Non Currrent Assets Other	Non Current Liabilities Total	Net Receivables	Net Tangible Assets
Total Assets		0.96	0.88	0.99	0.91	0.5	0.12	0.96	0.72	0.95	0.72	-0.46	0.95	0.71	0.99	0.97	0.96	-0.46	0.99	0.97	-0.25	0.67	0.78	0.93	0.98	0.17
Other Current Liab	0.96		0.91	0.97	0.88	0.38	0.03	0.98	0.73	0.88	0.73	-0.37	0.89	0.76	0.94	0.95	0.96	-0.37	0.96	0.89	-0.28	0.62	0.8	0.86	0.97	0.21
Total Current Liabilities	0.88	0.91		0.87	0.89	0.48	0.12	0.86	0.58	0.85	0.58	-0.37	0.83	0.63	0.88	0.89	0.83	-0.37	0.85	0.85	-0.13	0.46	0.66	0.71	0.87	0.01
Total Stockholder Equity	0.99	0.97	0.87		0.88	0.41	0.09	0.96	0.78	0.91	0.78	-0.44	0.95	0.73	0.98	0.96	0.98	-0.44	0.99	0.95	-0.22	0.7	0.83	0.92	0.96	0.22
Property Plant And Equipment Net	0.91	0.88	0.89	0.88		0.7	0.23	0.86	0.46	0.96	0.46	-0.48	0.83	0.59	0.94	0.95	0.8	-0.48	0.86	0.93	-0.3	0.35	0.51	0.85	0.92	-0.01
Net Debt	0.5	0.38	0.48	0.41	0.7		0.34	0.36	-0.22	0.74	-0.22	-0.43	0.43	0.19	0.57	0.56	0.24	-0.43	0.4	0.61	-0.21	0.06	-0.03	0.52	0.55	-0.49
Retained Earnings	0.12	0.03	0.12	0.09	0.23	0.34		-0.07	-0.06	0.23	-0.06	-0.88	0.24	-0.08	0.14	0.06	0.01	-0.88	0.12	0.24	0.4	0.07	0.05	0.01	0.05	-0.18
Accounts Payable	0.96	0.98	0.86	0.96	0.86	0.36	-0.07		0.74	0.85	0.74	-0.31	0.86	0.81	0.94	0.96	0.96	-0.31	0.96	0.89	-0.41	0.63	0.78	0.9	0.97	0.27
Cash	0.72	0.73	0.58	0.78	0.46	-0.22	-0.06	0.74		0.48	1.0	-0.22	0.74	0.55	0.66	0.62	0.87	-0.22	0.77	0.61	-0.01	0.73	0.86	0.62	0.62	0.59
Non Current Assets Total	0.95	0.88	0.85	0.91	0.96	0.74	0.23	0.85	0.48		0.48	-0.51	0.88	0.59	0.97	0.94	0.82	-0.51	0.9	0.96	-0.24	0.52	0.6	0.9	0.94	-0.08
Cash And Short Term Investments	0.72	0.73	0.58	0.78	0.46	-0.22	-0.06	0.74	1.0	0.48		-0.22	0.74	0.55	0.66	0.62	0.87	-0.22	0.77	0.61	-0.01	0.73	0.86	0.62	0.62	0.59
Common Stock Total Equity	-0.46	-0.37	-0.37	-0.44	-0.48	-0.43	-0.88	-0.31	-0.22	-0.51	-0.22		-0.54	-0.35	-0.47	-0.41	-0.37	1.0	-0.49	-0.58	-0.19	-0.38	-0.36	-0.39	-0.42	-0.01
Common Stock Shares Outstanding	0.95	0.89	0.83	0.95	0.83	0.43	0.24	0.86	0.74	0.88	0.74	-0.54		0.65	0.93	0.86	0.92	-0.54	0.95	0.93	-0.02	0.77	0.8	0.87	0.89	0.18
Other Current Assets	0.71	0.76	0.63	0.73	0.59	0.19	-0.08	0.81	0.55	0.59	0.55	-0.35	0.65		0.68	0.74	0.75	-0.35	0.78	0.73	-0.44	0.55	0.72	0.75	0.76	0.26
Total Liab	0.99	0.94	0.88	0.98	0.94	0.57	0.14	0.94	0.66	0.97	0.66	-0.47	0.93	0.68		0.98	0.93	-0.47	0.97	0.97	-0.27	0.64	0.72	0.93	0.98	0.11
Property Plant And Equipment Gross	0.97	0.95	0.89	0.96	0.95	0.56	0.06	0.96	0.62	0.94	0.62	-0.41	0.86	0.74	0.98		0.91	-0.41	0.95	0.95	-0.38	0.53	0.67	0.92	0.99	0.15
Total Current Assets	0.96	0.96	0.83	0.98	0.8	0.24	0.01	0.96	0.87	0.82	0.87	-0.37	0.92	0.75	0.93	0.91		-0.37	0.98	0.89	-0.24	0.75	0.87	0.88	0.93	0.37
Common Stock	-0.46	-0.37	-0.37	-0.44	-0.48	-0.43	-0.88	-0.31	-0.22	-0.51	-0.22	1.0	-0.54	-0.35	-0.47	-0.41	-0.37		-0.49	-0.58	-0.19	-0.38	-0.36	-0.39	-0.42	-0.01
Other Stockholder Equity	0.99	0.96	0.85	0.99	0.86	0.4	0.12	0.96	0.77	0.9	0.77	-0.49	0.95	0.78	0.97	0.95	0.98	-0.49		0.95	-0.24	0.73	0.84	0.93	0.96	0.24
Short Long Term Debt Total	0.97	0.89	0.85	0.95	0.93	0.61	0.24	0.89	0.61	0.96	0.61	-0.58	0.93	0.73	0.97	0.95	0.89	-0.58	0.95		-0.24	0.61	0.71	0.93	0.95	0.06
Short Term Debt	-0.25	-0.28	-0.13	-0.22	-0.3	-0.21	0.4	-0.41	-0.01	-0.24	-0.01	-0.19	-0.02	-0.44	-0.27	-0.38	-0.24	-0.19	-0.24	-0.24		0.08	-0.12	-0.41	-0.37	0.09
Current Deferred Revenue	0.67	0.62	0.46	0.7	0.35	0.06	0.07	0.63	0.73	0.52	0.73	-0.38	0.77	0.55	0.64	0.53	0.75	-0.38	0.73	0.61	0.08		0.83	0.63	0.62	0.31
Non Currrent Assets Other	0.78	0.8	0.66	0.83	0.51	-0.03	0.05	0.78	0.86	0.6	0.86	-0.36	0.8	0.72	0.72	0.67	0.87	-0.36	0.84	0.71	-0.12	0.83		0.69	0.72	0.24
Non Current Liabilities Total	0.93	0.86	0.71	0.92	0.85	0.52	0.01	0.9	0.62	0.9	0.62	-0.39	0.87	0.75	0.93	0.92	0.88	-0.39	0.93	0.93	-0.41	0.63	0.69		0.93	0.16
Net Receivables	0.98	0.97	0.87	0.96	0.92	0.55	0.05	0.97	0.62	0.94	0.62	-0.42	0.89	0.76	0.98	0.99	0.93	-0.42	0.96	0.95	-0.37	0.62	0.72	0.93		0.13
Net Tangible Assets	0.17	0.21	0.01	0.22	-0.01	-0.49	-0.18	0.27	0.59	-0.08	0.59	-0.01	0.18	0.26	0.11	0.15	0.37	-0.01	0.24	0.06	0.09	0.31	0.24	0.16	0.13

Click cells to compare fundamentals

ANI Pharmaceuticals Account Relationship Matchups

ANI Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	461.2M	771.6M	760.1M	904.4M	1.0B	1.1B
Other Current Liab	50.1M	60.0M	65.5M	99.8M	114.7M	120.5M
Total Current Liabilities	78.6M	87.5M	99.4M	145.5M	167.3M	175.7M
Total Stockholder Equity	195.7M	358.7M	338.5M	457.6M	526.2M	552.6M
Property Plant And Equipment Net	41.3M	52.7M	43.2M	44.6M	51.3M	53.8M
Net Debt	177.8M	187.1M	238.3M	64.5M	74.2M	38.9M
Retained Earnings	(5.0M)	(47.8M)	(97.3M)	(80.1M)	(72.1M)	(75.7M)
Accounts Payable	11.3M	23.0M	29.3M	36.7M	42.2M	44.3M
Cash	7.9M	100.3M	48.2M	221.1M	254.3M	267.0M
Non Current Assets Total	290.9M	449.8M	415.8M	384.6M	442.3M	464.4M
Cash And Short Term Investments	7.9M	100.3M	48.2M	221.1M	254.3M	267.0M
Common Stock Shares Outstanding	12.0M	12.6M	16.3M	18.2M	20.9M	22.0M
Liabilities And Stockholders Equity	461.2M	771.6M	760.1M	904.4M	1.0B	1.1B
Other Current Assets	5.9M	11.3M	25.2M	25.4M	29.2M	30.7M
Total Liab	265.5M	412.9M	421.5M	446.8M	513.8M	539.5M
Property Plant And Equipment Gross	41.3M	75.6M	76.0M	77.5M	89.2M	93.6M
Total Current Assets	170.3M	321.8M	344.3M	519.8M	597.8M	627.7M
Other Stockholder Equity	212.1M	384.7M	398.8M	504.0M	579.6M	608.6M
Accumulated Other Comprehensive Income	(11.4M)	(3.1M)	12.2M	8.9M	8.0M	8.4M
Short Long Term Debt Total	185.7M	287.4M	286.5M	285.7M	328.5M	344.9M
Short Term Debt	115.7M	9.9M	13.2M	850K	977.5K	928.6K
Current Deferred Revenue	451K	80K	87K	32.5M	37.4M	39.2M
Non Currrent Assets Other	802K	2.2M	2.6M	12.1M	13.9M	14.6M
Non Current Liabilities Total	186.9M	325.3M	322.1M	301.3M	346.5M	363.9M
Net Receivables	95.8M	128.5M	165.4M	162.1M	186.4M	195.7M
Net Tangible Assets	28.8M	3.6M	36.7M	58.7M	52.8M	55.5M
Other Assets	44.6M	57.5M	75.1M	92.7M	106.6M	112.0M
Long Term Debt	172.4M	286.5M	285.7M	284.8M	327.5M	343.9M
Retained Earnings Total Equity	17.6M	(5.0M)	(47.8M)	(97.3M)	(111.9M)	(117.5M)
Inventory	60.8M	81.7M	105.4M	111.2M	127.9M	134.3M
Deferred Long Term Liab	1.5M	800K	500K	600K	690K	458.1K
Intangible Assets	188.5M	294.1M	251.6M	209.0M	240.4M	156.5M
Property Plant Equipment	40.6M	41.3M	52.7M	43.2M	49.7M	52.2M
Capital Surpluse	200.8M	214.4M	387.8M	403.9M	464.5M	237.5M
Other Liab	7K	201K	31.0M	35.1M	40.3M	42.3M

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ANI Other Current Liab vs Current Deferred Revenue Analysis

Other Current Liab vs Current Deferred Revenue

Other Current Liab vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Other Current Liab

Current Deferred Revenue

ANI Pharmaceuticals fundamental ratios Correlations

ANI Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ANI Pharmaceuticals fundamental ratios Accounts

Additional Tools for ANI Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets
Other Stockholder Equity	+ 0.99	Total Assets
Other Stockholder Equity	+ 0.99	Total Stockholder Equity

Common Stock	- 0.88	Retained Earnings
Common Stock Total Equity	- 0.88	Retained Earnings
Short Long Term Debt Total	- 0.58	Common Stock
Short Long Term Debt Total	- 0.58	Common Stock Total Equity
Common Stock	- 0.54	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.54	Common Stock Total Equity